MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Statistical Methods in Clinical Trials
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,557 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,557 works in the cohort · of 4,299,418page 6 of 32

Labels cover 46 of 1,557 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,557 of 1,557 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Benefit and Harms of New Anti-Cancer Drugs
Francisco Vera-Badillo, Mustafa Al-Mubarak, Arnoud J. Templeton, Eitan Amir
2013· review· en· Current Oncology Reports· Mathematics
machine prediction:candidate · noneconsensus · none
34
citations
affunlabeled
Improving Alzheimer's disease phase II clinical trials
Barry Greenberg, María C. Carrillo, J. Michael Ryan, Michael Gold, Kim P. Gallagher, Michael Grundman +3 more
2012· article· en· Alzheimer s & Dementia· Mathematics
machine prediction:candidate · metaresearchconsensus · metaresearch
33
citations
afffundunlabeled
Adaptive designs in clinical trials: a systematic review-part I
Mohamed Ben‐Eltriki, Aisha Rafiq, Arun Paul, Devashree Prabhu, Michael Afolabi, Robert Baslhaw +9 more
2024· review· en· BMC Medical Research Methodology· Mathematics
machine prediction:candidate · metaresearchconsensus · none
32
citations
affunlabeled
Heterogeneity and Power in Clinical Biomarker Studies
Melania Pintilie, Vladimir V. Iakovlev, Anthony Fyles, David W. Hedley, Michael Milosevic, Rićhard P. Hill
2009· article· en· Journal of Clinical Oncology· Mathematics
machine prediction:candidate · metaresearchconsensus · metaresearch
31
citations
affunlabeled
Efficient Designs: Factorial Randomized Trials
Daniel B. Whelan, Katie N. Dainty, Jaskarndip Chahal
2012· article· en· Journal of Bone and Joint Surgery· Mathematics
machine prediction:candidate · metaresearchconsensus · none
29
citations
affunlabeled
Randomised trials at the level of the individual
Jay Park, Nathan Ford, Denis Xavier, Per Ashorn, Rebecca F. Grais, Zulfiqar A Bhutta +4 more
2021· review· en· The Lancet Global Health· Mathematics
machine prediction:candidate · metaresearchconsensus · metaresearch
29
citations

How this was built: Screen · Findings · About